IP Verse

Complexes Of Sirolimus And Its Derivatives, Process For The Preparation Thereof And Pharmaceutical Compositions Containing Them - EP3104844

The patent EP3104844 was granted to Druggability Holdco on Feb 12, 2020. The application was originally filed on Feb 13, 2015 under application number EP15710913A. The patent is currently recorded with a legal status of "Revoked".

EP3104844

DRUGGABILITY HOLDCO
Application Number
EP15710913A
Filing Date
Feb 13, 2015
Status
Revoked
Apr 15, 2022
Publication Date
Feb 12, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALKERMES PHARMA IRELANDNov 11, 2020ATKINS -

Patent Citations (58) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONCA2078379
DESCRIPTIONEP0650357
DESCRIPTIONEP1273288
DESCRIPTIONEP1670437
DESCRIPTIONEP1781671
DESCRIPTIONEP1871343
DESCRIPTIONEP2402350
DESCRIPTIONEP2480207
DESCRIPTIONEP2522338
DESCRIPTIONEP2575889
DESCRIPTIONJP2005312967
DESCRIPTIONUS2005025810
DESCRIPTIONUS2005032680
DESCRIPTIONUS2005239724
DESCRIPTIONUS2006251710
DESCRIPTIONUS2006263409
DESCRIPTIONUS2008138405
DESCRIPTIONUS2008176888
DESCRIPTIONUS2009068266
DESCRIPTIONUS2009130210
DESCRIPTIONUS2010098770
DESCRIPTIONUS2010183728
DESCRIPTIONUS2011009325
DESCRIPTIONUS2011076308
DESCRIPTIONUS2012022095
DESCRIPTIONUS2013039951
DESCRIPTIONUS2013150397
DESCRIPTIONUS2013225631
DESCRIPTIONUS2013280336
DESCRIPTIONUS6239102
DESCRIPTIONUS6565859
DESCRIPTIONWO2006094507
DESCRIPTIONWO2006101972
DESCRIPTIONWO2006123226
DESCRIPTIONWO2007079560
DESCRIPTIONWO2007091059
DESCRIPTIONWO2008022557
DESCRIPTIONWO2010130982
DESCRIPTIONWO2011128910
DESCRIPTIONWO2011135580
DESCRIPTIONWO2012142145
DESCRIPTIONWO2013022201
INTERNATIONAL-SEARCH-REPORTEP1759724
INTERNATIONAL-SEARCH-REPORTEP1952807
INTERNATIONAL-SEARCH-REPORTUS2013039951
INTERNATIONAL-SEARCH-REPORTUS2013150397
INTERNATIONAL-SEARCH-REPORTWO2006094507
OPPOSITIONEP0868911
OPPOSITIONUS4826689
OPPOSITIONUS5154684
OPPOSITIONWO03024424
OPPOSITIONWO2006101972
OPPOSITIONWO2009133418
OPPOSITIONWO2010146406
OPPOSITIONWO2010146407
OPPOSITIONWO2010146408
OPPOSITIONWO2010146409
OPPOSITIONWO2011158053

Non-Patent Literature (NPL) Citations (13) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- AD ORMEROD, BR J DERMATOL, (2005), vol. 152, no. 4, pages 758 - 64
DESCRIPTION- B MADKE, INDIAN DERMATOL ONLINE J., (2013), vol. 4, no. 1, pages 54 - 57
DESCRIPTION- LASERS SURG MED., (2012), vol. 44, no. 10, pages 796 - 804
DESCRIPTION- M. KANSI ET AL., JOURNAL OF MEDICINAL CHEMISTRY, (1998), vol. 41, page 1007
DESCRIPTION- S. BENDELS ET AL., PHARMACEUTICAL RESEARCH, (2006), vol. 23, page 2525
OPPOSITION- Anonymous, "Rapamune® (sirolimus) Oral Solution and Tablets", Wyeth Pharmaceuticals Inc.,, (20040119), pages 1 - 39, XP055756186
OPPOSITION- Jasmine M. Rowe, Keith P. Johnston, "Chapter 12- Precipitation Technologies for Nanoparticle Production", Jasmine M. Rowe, Keith P. Johnston, Robert O. Williams III, Alan B. Watts, Dave A, Miller, Formulating Poorly Water Soluble Drugs, Springer, (2012), pages vi-x, 501-505, 532-545, 552-553, 602-603, 620 - 621, XP055756199
OPPOSITION- JUNGHANNS JENS-UWE A H; ET AL, "Nanocrystal technology, drug delivery and clinical applications", INTERNATIONAL JOURNAL OF NANOMEDICINE,, (20080000), vol. 3, no. 3, pages 295 - 309, XP002740187
OPPOSITION- Krisztian Niesz; Istvan Hornyak; Bernadett Borcsek; Ferenc Darvas, "Nanoparticle synthesis completed with in situ catalyst preparation performed on a high-pressure high-temperature continuous flow reactor", Microfluidics and Nanofluidics, (20080125), vol. 5, no. 3, pages 411 - 416, XP019597938
OPPOSITION- Angi Réka; Solymosi Tamás; Ötvös Zsolt; Ordasi Betti; Glavinas Hristos; Filipcsei Genovéva; Heltovics Gábor; Darvas Ferenc, "Novel continuous flow technology for the development of a nanostructured Aprepitant formulation with improved pharmacokinetic properties", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS,, (20140000), vol. 86, no. 3, pages 361 - 368, XP028845346
OPPOSITION- Solymosi Tamás; Angi Réka; Basa-Dénes Orsolya; Ránky Soma; Ötvös Zsolt; Glavinas Hristos; Filipcsei Genovéva; Heltovics Gábor, "Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS,, (20150521), vol. 94, pages 135 - 140, XP029248484
OPPOSITION- Ali H S M; York P; Blagden N, "Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors", Int J Pharmaceutics, (20090405), vol. 375, pages 107 - 113, XP026143342
OPPOSITION- Sung-Joo Hwang, Min-Soo Kim, Jeong-Soo Kim, Hee Jun Park, Won Kyung Cho, Kwang-Ho Cha, "Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process", Int J Nanomed, (20111124), vol. 6, pages 2997 - 3009, XP055756175

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents